CSBR
Champions Oncology Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs.
Champions Oncology, Inc. (CSBR) is rated C+ (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Value (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | D+ (1.8) | C (2.2) | B (3.4) | C+ (2.5) | C+ (2.6) | C+ (2.5) |
| 2026-11-04 | D+ (1.7) | C (2.3) | B (3.4) | C (2.4) | C+ (2.7) | C+ (2.5) |
| 2026-10-28 | D+ (1.8) | C (2.2) | B (3.4) | C (2.2) | C+ (2.7) | C (2.4) |
| 2026-10-21 | D+ (1.7) | C (2.2) | B (3.4) | C- (2.1) | C+ (2.6) | C (2.4) |
| 2026-10-14 | D+ (1.8) | C (2.2) | B (3.4) | C- (2.1) | C+ (2.6) | C (2.4) |